Metastatik Gastrik Karsinomlu Bir Olguda Metoklopropamid İlişkili Nöroleptik Malign Sendrom

  • Meltem Baykara
  • Efnan Algin
  • Süleyman Büyükberber
  • Gülnihal Tufan
  • Burçak Cavnar
  • Umut Demirci
  • Uğur Coşkun
  • Mustafa Benekli

Abstract

Nöroleptik Malign Sendrom (NMS), hipertermi, müsküler rijidite, şuur değişikliği, otonomik disfonksiyon, serum kreatinfosfokinaz (CPK) düzeyinde yükselme ve lökositoz ile karakterize olup; nadir görülen ve fatal seyredebilen bir sendromdur. Metoklopropamid ilişkili NMS nadir fakat hayatı tehtid eden bir durumdur. Metoklopropamid ilişkili NMS, metoklopropamidin beyindeki dopamin reseptörlerini bloke etmesi ve güçlü kolinerjik stimulasyon etkisi sonucu ortaya çıkmaktadır. Biz burada metastatik mide kanseri tanısıyla takip edilirken emezis nedeniyle metoklopropamid kullanımı sonrasında NMS gelişen bir olguyu sunuyoruz.

References

Robinson MB, Kennett RP, Harding AE, Legg NJ, Clarke B. Neuroleptic malignant syndrome associated with metoclopramide. J Neurol Neurosurg Psychiatry 1985; 48:1304.

Jackson N, Doherty J, Coulter S. Neuropsychiatric complications of commonly used palliative care drugs. Postgrad Med J 2008; 84:121-6.

Norris B, Angeles V, Eisenstein R, Seale JP. Neuroleptic malignant syndrome with delayed onset of fever following risperidone administration. Ann Pharmacother 2006;40:2260-4.

Norgard NB, Stark JE. Olanzapine-associated neuroleptic malignant syndrome. Pharmacotherapy 2006;26:1180-2.

Knight ME, Roberts RJ. Phenothiazine and butyrophenone intoxication in children. Pediatr Clin North Am 1986;33:299-309.

Bond WS. Detection and management of the neuroleptic malignant syndrome. Clin Pharm 1984;3:302-7.

Kawanishi C, Onishi H, Kato D, Yamada T, Onose M, Hirayasu Y. Neuroleptic malignant syndrome in cancer treatment. Palliat Support Care 2005;3:51-3.

Spivak B, Gonen N, Mester R, Averbuch E, Adlersberg S, Weizman A. Neuroleptic malignant syndrome associated with abrupt withdrawal of anticholinergic agents. Int Clin Psychopharmacol 1996;11:207-9.

Tanii H, Fujita K, Okazaki Y. Neuroleptic malignant syndrome related to a switch to perospirone and anticholinergic withdrawal. Am J Psychiatry 2006;163:547-8.

Patterson J F. Neuroleptic malignant syndrome associated with metoclopramide. Southern Medical Journal 1988; 81:674-5.

Cassidy T, Bansal SK. Neuroleptic malignant syndrome associated with metoclopramide. British Medical Journal 1988;296:214.

Krähenbühl S, Raisin J, Herren T. Malignant neuroleptic syndrome under metoclopramide and neuroleptics in anuria. Schweiz Med Wochenschr 1993; 123:1359-62.

Bakri YN, Khan R, Subhi J, Kawi Z. Neuroleptic malignant syndrome associated with metoclopramide antiemetic therapy. Gynecol Oncol 1992; 44:189-90.

Brower RD, Dreyer CF, Kent TA. Neuroleptic malignant syndrome in a child treated with metoclopramide for chemotherapy related nausea. J Child Neurol 1989;4:230-2.

Sanai T, Matsui R, Hirano T, Torichigai S, Yotsueda H, Higashi H, Hirakata H, Iida M. Successful treatment of six patients with neuroleptic malignant syndrome associated with myoglobulinemic acute renal failure. Ren Fail 2006;28:51-5.

Kasantikul D, Kanchanatawan B. Neuroleptic malignant syndrome: a review and report of six cases. J Med Assoc Thai 2006;89:2155-60.

Jackson N, Doherty J, Coulter S. Neuropsychiatric complications of commonly used palliative care drugs. Postgrad Med J 2008;84:121-6.

Published
2013-06-28